Insights Into Multiple Myeloma (MM) 2024
Perspectives on current treatment practices regarding frontline therapy of MM, the evolving role of MRD testing in MM, treatment in later lines of therapy, and attitudes toward recently introduced agents
Select Report
Florida – February 9, 2024
Faculty Chair
Melissa Alsina, MD
Moffitt Cancer Center, Tampa, FL, USA
More Information
- Tampa, FL
- Florida
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of MM
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies are obtained: bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, pomalidomide, thalidomide, melphalan, cyclophosphamide, bendamustine, panobinostat, selinexor, isatuximab, and venetoclax
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
